Global Diabetes Drugs Market Is Expected To Be Worth US$58.4 Bn By The End Of 2025, Expected To Surge At A CAGR Of 3.6%

Researchmoz added Most up-to-date research on "Diabetes Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its huge collection of research reports.

This report on the Diabetes drugs market analyzes the current and future scenario of the global market. Rise in private and public funding for diabetes drugs, rising prevalence of diabetes, and favorable regulatory scenario for new drug launch are boosting the growth of the Diabetes drugs market. Increasing geriatric population across the world and rising incidence and prevalence of diabetes such as Type 2 diabetes and Type 1 diabetes are some of the factors expected to drive the growth of Diabetes drugs market during the forecast period.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1461379

The diabetes drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on therapy, disease type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints, opportunities and trends have been provided in the market overview section. Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Diabetes drugs market.

Global Diabetes Drugs Market: Segmentation

Based on the therapy, the Diabetes drugs market has been segmented into 5 types, which are Glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin and others. . The insulin dominated the market in terms of revenue in 2016, due to its high price, and need & demand for insulin. Insulin is expected to lead the market in the forecast period, owing to the rising geriatric population and high per capita income. SGLT2 is anticipated to grow during the forecast period owing to patents and exclusivity held for the drugs of this segment by the key players. The others segment includes the combination drugs and other drug classes are anticipated to grow during the forecast period 2017 to 2025. The Glucagon-like peptide-1 (GLP-1) agonist is anticipated to grow during the forecast period owing to rising prevalence of diabetes all over the world.Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share in 2016, however, the segment is anticipated to fall in the growth rate during the forecast period due to patent and exclusivity expiry.

In terms of disease type, the diabetes drugs market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. Type 2 diabetes has accounted for highest market share due to increasing disposable income and rising prevalence of obesity. Increasing physical inactivity created demand for the diabetes drugs. Type 1 diabetes held the second large market share in 2016 owing to increasing environmental damage all over the world that is contributing to the rising prevalence of type 1 diabetes. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are anticipated to grow during the forecast period 2017 to 2025 due to the high prevalence of diabetes in the relatives and heredity reason.

Different types of distribution channels are present in the diabetes drugs market those are Hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies captured highest market share in 2016, owing to the availability of trained & qualified personnel and favorable reimbursement structure. The online pharmacies is estimated to register highest CAGR in the forecast period, which is attributed to the technological adaptation and acceptance of online pharmacies by population. The retail pharmacies showed the moderate market share in 2016 owing to rising geriatric population & improvements in the healthcare facilities in developing countries are anticipated to propel the popularity of retail pharmacies during the forecast period. However, uncertain reimbursement scenarios across the world are attributed to restrain the diabetes drugs market to some extent during the forecast period.

Global Diabetes Drugs Market: Regional Segmentation

Geographically, the diabetes drugs Market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).

Global Diabetes Drugs Market: Competitive Landscape

The report also profiles major players in the Diabetes drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/diabetes-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html/toc

Diabetes Drugs Market has been segmented as given below:

Diabetes Drugs Market, by Therapy

Glucagon-like peptide-1 (GLP-1) agonist
Dipeptidyl-peptidase-4 (DPP-4) inhibitors
Sodium glucose co-transporter 2 (SGLT2) inhibitors
Insulin
Others

Diabetes Drugs Market, by Disease Type

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Impaired Glucose Tolerance and Impaired Fasting Glycaemia

Diabetes Drugs Market, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Diabetes Drugs Market, by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Mexico
- Rest of Latin America

Latest Report on Global Diabetes Drugs Market to 2023 | GLP-1 Receptor Agonists and SGLT-2 Inhibitors

Researchmoz added Most up-to-date research on "Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes" to its huge collection of research reports.

This report provides insight into the diversifying and highly lucrative diabetes mellitus (DM) market. Analysis has identified a high level of diversification in the market, which is of vital importance for investors and key market players. Furthermore, the report provides insight into groundbreaking drugs, and the threats that they are likely to encounter over the forecast period. Also identified are opportunities for investment and co-marketing in key BRIC economies, where the yearly incidence of T1DM is set to exceed the total number of T1DM patients in the US.

This report also comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

Get Comple TOC With Tables and Figures @ https://www.researchmoz.us/global-diabetes-drugs-market-to-2023-a-diversifying-treatment-landscape-as-glp-1-receptor-agonists-and-sglt-2-inhibitors-gain-ground-following-landmark-cardiac-outcomes-report.html/toc

There is a high unmet clinical need to develop favorable routes of administration for insulin products. Likewise, there is high unmet need for a curative or prophylactic treatment for both T1DM and T2DM.

There are currently over 800 products in the DM pipeline, with developmental molecules generally being aimed at improving on existing products. Most pipeline molecules are insulin or GLP-1 agonists. There are several combination therapy trials for the use of insulin receptor/GLP-1 agonists with other compounds - particularly SGLT-2 inhibitors. Among these products, an entirely novel SGLT1/2 inhibitor is expected to enter the market, and is expected to become a blockbuster drug, achieving licensed status for both T1DM and T2DM.

Scope

- Global revenue from the DM market between 2016 and 2023
- Novel compounds and new drugs achieving blockbuster status by 2023
- Analysis of market share changes for leading compounds by 2023
- Analysis of leading companies by market share
- Analysis of deals conducted during the 2006-2017 period

Reasons to buy

- Understand the current treatment landscape, with profile assessments of key marketed products and a focus on historical and forecast sales patterns.
- Gain insight into a highly diversifying market for DM products, and the factors behind the significant changes projected in market share between key compounds.
- Analyze the DM pipeline through a comprehensive review of products, segmented by stage of development, molecule type and molecular target - as well as detailed profile assessments and multi-scenario revenue projections for the most promising late-stage pipeline candidates.
- Consider market opportunities and potential risks associated with attempting to bring pipeline products to market by examining trends in clinical trial size, duration and failure rate by stage of development, key indication, molecule type and molecular target.
- Predict growth in market size, with multi-scenario forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify the leading companies in the DM market and understand the factors that will influence growth and market share with profile assessments of key companies, including multi-scenario revenue projections.
- Identify commercial opportunities in the DM deals landscape by analyzing trends in licensing and co-development deals.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1370886

Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 10
2.1 Overview 10
2.2 Classification of Diabetes 10
2.3 Symptoms 11
2.4 Diagnostic Criteria 11
2.5 Etiology 12
2.5.1 T1DM 12
2.5.2 T2DM 13
2.6 Pathophysiology 14
2.6.1 Physiology of Glucose Metabolism 14
2.6.2 T1DM Pathophysiology 15
2.6.3 T2DM Pathophysiology 16
2.7 Epidemiology 17
2.7.1 T1DM 18
2.7.2 T2DM 19
2.8 Comorbidities and Complications 20
2.9 Treatments 21
2.9.1 Insulin Therapy 21
2.9.2 Insulin Secretagogues 22
2.9.3 Thiazolidinediones 23
2.9.4 Biguanides 23
2.9.5 Dipeptidyl Peptidase 4 Inhibitors 23
2.9.6 Glucagon-Like Peptide-1 Receptor Agonists 24
2.9.7 Sodium-Glucose Co-Transporter-2 Inhibitors 24
2.9.8 Amylin Analogs 24
2.9.9 Combination Therapies 25
2.9.10 Non-pharmacological Therapy 25

3 Key Marketed Products 27
3.1 Overview 27
3.1.1 Market Share of the Top Five Grossing Drugs in 2016 27
3.1.2 Market Share of the Five Strongest Growing Blockbuster Drugs 28
3.2 Long-Acting Insulin Therapies (Basal Insulins) 29
3.2.1 Lantus (insulin glargine) - Sanofi 29
3.2.2 Levemir (insulin detemir) - Novo Nordisk 31
3.2.3 Tresiba (insulin degludec) - Novo Nordisk 32
3.2.4 Toujeo (insulin glargine) - Sanofi 33
3.3 Short-Acting Insulin Therapies (Bolus Insulins) 35
3.3.1 Humalog (insulin lispro) - Eli Lilly 35
3.3.2 Novolog (Insulin aspart) - Novo Nordisk 36
3.3.3 Apidra (insulin glulisine) - Sanofi 38
3.4 GLP-1 Receptor Agonists 39
3.4.1 Victoza (liraglutide) - Novo Nordisk 39
3.4.2 Trulicity (dulaglutide) - Eli Lilly 41
3.5 DPP-4 Inhibitors 42
3.5.1 Januvia (sitagliptin) - Merck and Co 42
3.5.2 Galvus (vildagliptin) - Novartis 44
3.5.3 Tradjenta (linagliptin) - Boehringer Ingelheim 45
3.6 SGLT-2 Inhibitors 46
3.6.1 Invokana (canagliflozin) - Johnson and Johnson 46
3.6.2 Jardiance (empagliflozin) - Boehringer Ingelheim 47
3.6.3 Farxiga (dapagliflozin) - AstraZeneca 49
3.7 Combination Therapies 50
3.7.1 Soliqua 100/33 (insulin glargine and lixisenatide) - Sanofi 50
3.7.2 Xultophy (insulin degludec and liraglutide) - Novo Nordisk 51
3.7.3 Janumet - Merck 52
3.7.4 Qtern (saxagliptin and dapagliflozin) - AstraZeneca 53
3.8 Unmet Needs 54
3.9 Conclusion 55

4 Pipeline Landscape Assessment 56
4.1 Overview 56
4.2 Pipeline Development Landscape 57
4.3 Molecular Targets in the Pipeline 59
4.4 Clinical Trials Landscape 61
4.4.1 Clinical Trial Failure Rates 62
4.4.2 Clinical Trial Duration 66
4.4.3 Clinical Trial Size 69
4.4.4 Aggregate Clinical Program Size 73
4.5 Assessment of Key Pipeline Products 76
4.5.1 Semaglutide (NN-9535) - Novo Nordisk 76
4.5.2 Oral Semaglutide (OG-217SC) - Novo Nordisk 77
4.5.3 ITCA 650 - Intarcia 78
4.5.4 Sotagliflozin - Lexicon Pharmaceuticals and Sanofi 79
4.5.5 Ertugliflozin - Merck and Co and Pfizer 81

5 Multi-scenario Market Forecast to 2023 82
5.1 Overall Market Size 82
5.2 Generic Penetration 86
5.3 Revenue Forecast by Molecular Target 88
5.3.1 Insulin Receptors 89
5.3.2 GLP-1 Receptors 90
5.3.3 SGLT-2 Inhibitors 90
5.3.4 DPP-4 Inhibitors 91

6 Company Analysis and Positioning 93
6.1 Revenue and Market Share Analysis by Company 93
6.1.1 Novo Nordisk - Sales from Recently Approved and Upcoming Products to Increase Already Substantial Market Share 97
6.1.2 Eli Lilly - Strong Growth to Result in Elevation to Second Place in Market 99
6.1.3 Sanofi - Large Market Share Loss Due to Declining Sales of Lantus 100
6.1.4 AstraZeneca - Growth in Revenue Largely Attributable to Farxiga Sales 101
6.1.5 Johnson and Johnson - Continued Uptake of Invokana to Drive Market Growth 102
6.1.6 Merck & Co - Patent Expiry of Januvia to Limit Growth 103
6.2 Company Landscape 104
6.3 Marketed and Pipeline Portfolio Analysis 104

Continue...

Browse Detail Report @ https://www.researchmoz.us/global-diabetes-drugs-market-to-2023-a-diversifying-treatment-landscape-as-glp-1-receptor-agonists-and-sglt-2-inhibitors-gain-ground-following-landmark-cardiac-outcomes-report.html